Aripiprazole Treatment of the Prodrome

Status Terminated

Clinical Trial Summary

The RAP Program is conducting a research study of the antipsychotic medication Aripiprazole. This drug has been approved for treating symptoms associated with schizophrenia and is associated with fewer side effects. This study will explore how well Aripiprazole treats symptoms of early-onset psychotic disorders as well as symptoms that may indicate risk for such disorders, including unusual thoughts, suspiciousness, perceptual abnormalities, social isolation, and sudden changes in functioning.

Clinical Trial Description

During the 12-week study, eligible patients are seen 7-9 times by research raters and psychiatrists. These visits include side effect monitoring, scheduled medication increases, and ratings designed to measure subtle improvement of symptoms. Monthly blood and urine samples are collected for safety and substance abuse monitoring, and neuropsychological testing is conducted at the first and last appointments. Participants are compensated for their participation and receive medication and study-related visits at no cost during the trial. Depending on their level of response to the medication, participants may also be eligible for a 3-month extension phase. ;

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00169949
Study type	Interventional
Source	Northwell Health
Contact
Status	Terminated
Phase	N/A
Start date	January 2004
Completion date	May 2006

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT03149107` - "Multimodal Prevention of Psychosis - Investigating Efficacy of N-Acetylcysteine and Psychotherapy in CHR-Patients"	Phase 3
Recruiting	`NCT05131035` - Targeting Processing Speed Deficits to Improve Social Functioning and Lower Psychosis Risk	N/A
Completed	`NCT01269710` - Second-Generation Antipsychotic Treatment Indication Effectiveness And Tolerability In Youth (Satiety) Study	N/A
Enrolling by invitation	`NCT05567848` - Accelerated TMS in Psychosis	Phase 1/Phase 2
Recruiting	`NCT03751865` - Early Detection and Intervention for Women At-risk of Psychosis	N/A
Recruiting	`NCT05052853` - Early Intervention of Prodromal Schizophrenia Using an NMDA Enhancer	Phase 2
Recruiting	`NCT05877716` - EPI-MINN: Targeting Cognition and Motivation - National	N/A
Completed	`NCT01597141` - Psychosis: Early Detection, Intervention and Prevention	N/A
Completed	`NCT00169988` - Antidepressant and Antipsychotic to Treat Attenuated Positive and Negative Symptoms	N/A
Completed	`NCT03447548` - Neurofeedback Training for High Risk Psychosis	N/A
Completed	`NCT06190483` - Investigating the Role of Diazepam on Brain Function and Chemistry in Psychosis Risk	N/A
Completed	`NCT01619319` - Effects of Cognitive Remediation on Cognition in Young People at Clinical High Risk of Psychosis	N/A
Recruiting	`NCT05167396` - REtinal and VIsual Cortical Response in Early PSYchosis	N/A
Recruiting	`NCT04338152` - Family-Focused Therapy for Individuals at High Clinical Risk for Psychosis: A Confirmatory Efficacy Trial	N/A
Recruiting	`NCT05142735` - Effects of NAC on Symptoms of CHR Patients	N/A
Enrolling by invitation	`NCT05532683` - Feasibility Trial of a Lifestyle Intervention for CHR-P	N/A
Enrolling by invitation	`NCT03970005` - Evaluation of Step-Based Care for Individuals at Clinical High Risk for Psychosis